Document is current

Article History

Received: 7 November 2023

Accepted: 21 December 2023

First Online: 7 February 2024

Declarations

:

: José Manuel Carrascosa has participated as IP/SI and/or invited speaker and/or invited advisor and/or member of steering committee for Gebro, Nordic Pharma, Leo Pharma, Abbvie, Janssen, Pfizer, Novartis, Galderma, Sanofi, Almirall, UCB, Lilly, Sandoz, Boehringer Ingelheim and Bristol Myers Squibb. Susan Ramirez, Mónica Valderrama and María Montoro Álvarez work at Pizer S.L.U. Ana Echarri has collaborated as a speaker, consultant, or has received research or education funding from Janssen, AbbVie, Pfizer, Galapagos and MSD-Spain., Olga Gavín Sebastián, Paloma García de la Peña and, Oscar Martínez Pérez have nothing to disclose.

: As this study was classified as a consensus development technique and did not involve research on patients or patients’ data, obtaining approval from an ethics committee or internal review board was not necessary. All the clinicians who participated in this study willingly served as panelists, agreed with the objectives of the modified Delphi panel study, actively contributed to manuscript development, and consented to the publication of this manuscript. Doctors who filled in the Delphi questionnaire received an explanation about the project; they were informed about the intention to publish results and asked to complete the Delphi questionnaire if they agreed. It was optional to answer anonymously or provide names to appear in acknowledgements.